Accelerating Sampling and Aggregation Operations in GNN Frameworks with GPU Initiated Direct Storage Accesses

Graph Neural Networks (GNNs) are emerging as a powerful tool for learning from graph-structured data and performing sophisticated inference tasks in various application domains. Although GNNs have been shown to be effective on modest-sized graphs, training them on large-scale graphs remains a significant challenge due to lack of efficient data access and data movement methods. Existing frameworks for training GNNs use CPUs for graph sampling and feature aggregation, while the training and updating of model weights are executed on GPUs. However, our in-depth profiling shows the CPUs cannot achieve the throughput required to saturate GNN model training throughput, causing gross under-utilization of expensive GPU resources. Furthermore, when the graph and its embeddings do not fit in the CPU memory, the overhead introduced by the operating system, say for handling page-faults, comes in the critical path of execution. To address these issues, we propose the GPU Initiated Direct Storage Access (GIDS) dataloader, to enable GPU-oriented GNN training for large-scale graphs while efficiently utilizing all hardware resources, such as CPU memory, storage, and GPU memory with a hybrid data placement strategy. By enabling GPU threads to fetch feature vectors directly from storage, GIDS dataloader solves the memory capacity problem for GPU-oriented GNN training. Moreover, GIDS dataloader leverages GPU parallelism to tolerate storage latency and eliminates expensive page-fault overhead. Doing so enables us to design novel optimizations for exploiting locality and increasing effective bandwidth for GNN training. Our evaluation using a single GPU on terabyte-scale GNN datasets shows that GIDS dataloader accelerates the overall DGL GNN training pipeline by up to 392X when compared to the current, state-of-the-art DGL dataloader.Comment: Under Submission. Source code: https://github.com/jeongminpark417/GID

Venous Thromboembolism in Cancer: An Update of Treatment and Prevention in the Era of Newer Anticoagulants

Cancer patients are at major risk of developing Venous Thromboembolism (VTE), resulting in increased morbidity and economic burden. While a number of theories try to explain its pathophysiology, its risk stratification can be broadly done in cancer related, treatment related and patient related factors. Studies report the prophylactic use of thrombolytic agents to be safe and effective in decreasing VTE related mortality/ morbidity especially in postoperative cancer patients. Recent data also suggests the prophylactic use of low molecular weight Heparins (LMWH’s) and Warfarin to be effective in reducing VTE’s related to long term Central Venous Catheter (CVC) use. In a double blind, multicenter trial, a new Ultra LMWH Semuloparin has shown to be efficacious in preventing chemotherapy associated VTE’s along with other drugs such as Certoparin and Nadoparin.. LMWH’s are reported to be very useful in preventing recurrent VTE’s in advanced cancers and should be preferred over full dose Warfarin. However their long term safety beyond 6 months has not been established yet. Further, this manuscript discusses the safety and efficacy of different drugs used in the treatment and prevention of recurrent VTE’s including Bemiparin, Semuloparin, oral direct thrombin inhibitors, parenteral and direct oral factor Xa inhibitors

Potentially Guided Bidirectionalized RRT* for Fast Optimal Path Planning in Cluttered Environments

Rapidly-exploring Random Tree star (RRT*) has recently gained immense popularity in the motion planning community as it provides a probabilistically complete and asymptotically optimal solution without requiring the complete information of the obstacle space. In spite of all of its advantages, RRT* converges to optimal solution very slowly. Hence to improve the convergence rate, its bidirectional variants were introduced, the Bi-directional RRT* (B-RRT*) and Intelligent Bi-directional RRT* (IB-RRT*). However, as both variants perform pure exploration, they tend to suffer in highly cluttered environments. In order to overcome these limitations we introduce a new concept of potentially guided bidirectional trees in our proposed Potentially Guided Intelligent Bi-directional RRT* (PIB-RRT*) and Potentially Guided Bi-directional RRT* (PB-RRT*). The proposed algorithms greatly improve the convergence rate and have a more efficient memory utilization. Theoretical and experimental evaluation of the proposed algorithms have been made and compared to the latest state of the art motion planning algorithms under different challenging environmental conditions and have proven their remarkable improvement in efficiency and convergence rate

CODAG: Characterizing and Optimizing Decompression Algorithms for GPUs

Data compression and decompression have become vital components of big-data applications to manage the exponential growth in the amount of data collected and stored. Furthermore, big-data applications have increasingly adopted GPUs due to their high compute throughput and memory bandwidth. Prior works presume that decompression is memory-bound and have dedicated most of the GPU's threads to data movement and adopted complex software techniques to hide memory latency for reading compressed data and writing uncompressed data. This paper shows that these techniques lead to poor GPU resource utilization as most threads end up waiting for the few decoding threads, exposing compute and synchronization latencies. Based on this observation, we propose CODAG, a novel and simple kernel architecture for high throughput decompression on GPUs. CODAG eliminates the use of specialized groups of threads, frees up compute resources to increase the number of parallel decompression streams, and leverages the ample compute activities and the GPU's hardware scheduler to tolerate synchronization, compute, and memory latencies. Furthermore, CODAG provides a framework for users to easily incorporate new decompression algorithms without being burdened with implementing complex optimizations to hide memory latency. We validate our proposed architecture with three different encoding techniques, RLE v1, RLE v2, and Deflate, and a wide range of large datasets from different domains. We show that CODAG provides 13.46x, 5.69x, and 1.18x speed up for RLE v1, RLE v2, and Deflate, respectively, when compared to the state-of-the-art decompressors from NVIDIA RAPIDS

ADHD presenting as recurrent epistaxis: a case report

Epistaxis is an important otorhinolaryngological emergency, which usually has an apparent etiology, frequently local trauma in children. Here we present a case report wherein the epistaxis was recalcitrant, and proved to have a psychiatric disorder as an underlying basis. The child was diagnosed with Attention Deficit/Hyperactivity Disorder, hyperactive type, which led to trauma to nasal mucosa due to frequent and uncontrolled nose picking. Treatment with atomoxetine controlled the patient's symptoms and led to a remission of epistaxis

The global burden of trichiasis in 2016.

BACKGROUND: Trichiasis is present when one or more eyelashes touches the eye. Uncorrected, it can cause blindness. Accurate estimates of numbers affected, and their geographical distribution, help guide resource allocation. METHODS: We obtained district-level trichiasis prevalence estimates in adults for 44 endemic and previously-endemic countries. We used (1) the most recent data for a district, if more than one estimate was available; (2) age- and sex-standardized corrections of historic estimates, where raw data were available; (3) historic estimates adjusted using a mean adjustment factor for districts where raw data were unavailable; and (4) expert assessment of available data for districts for which no prevalence estimates were available. FINDINGS: Internally age- and sex-standardized data represented 1,355 districts and contributed 662 thousand cases (95% confidence interval [CI] 324 thousand-1.1 million) to the global total. Age- and sex-standardized district-level prevalence estimates differed from raw estimates by a mean factor of 0.45 (range 0.03-2.28). Previously non- stratified estimates for 398 districts, adjusted by ×0.45, contributed a further 411 thousand cases (95% CI 283-557 thousand). Eight countries retained previous estimates, contributing 848 thousand cases (95% CI 225 thousand-1.7 million). New expert assessments in 14 countries contributed 862 thousand cases (95% CI 228 thousand-1.7 million). The global trichiasis burden in 2016 was 2.8 million cases (95% CI 1.1-5.2 million). INTERPRETATION: The 2016 estimate is lower than previous estimates, probably due to more and better data; scale-up of trichiasis management services; and reductions in incidence due to lower active trachoma prevalence

Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021

BACKGROUND Regular, detailed reporting on population health by underlying cause of death is fundamental for public health decision making. Cause-specific estimates of mortality and the subsequent effects on life expectancy worldwide are valuable metrics to gauge progress in reducing mortality rates. These estimates are particularly important following large-scale mortality spikes, such as the COVID-19 pandemic. When systematically analysed, mortality rates and life expectancy allow comparisons of the consequences of causes of death globally and over time, providing a nuanced understanding of the effect of these causes on global populations. METHODS The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021 cause-of-death analysis estimated mortality and years of life lost (YLLs) from 288 causes of death by age-sex-location-year in 204 countries and territories and 811 subnational locations for each year from 1990 until 2021. The analysis used 56 604 data sources, including data from vital registration and verbal autopsy as well as surveys, censuses, surveillance systems, and cancer registries, among others. As with previous GBD rounds, cause-specific death rates for most causes were estimated using the Cause of Death Ensemble model-a modelling tool developed for GBD to assess the out-of-sample predictive validity of different statistical models and covariate permutations and combine those results to produce cause-specific mortality estimates-with alternative strategies adapted to model causes with insufficient data, substantial changes in reporting over the study period, or unusual epidemiology. YLLs were computed as the product of the number of deaths for each cause-age-sex-location-year and the standard life expectancy at each age. As part of the modelling process, uncertainty intervals (UIs) were generated using the 2·5th and 97·5th percentiles from a 1000-draw distribution for each metric. We decomposed life expectancy by cause of death, location, and year to show cause-specific effects on life expectancy from 1990 to 2021. We also used the coefficient of variation and the fraction of population affected by 90% of deaths to highlight concentrations of mortality. Findings are reported in counts and age-standardised rates. Methodological improvements for cause-of-death estimates in GBD 2021 include the expansion of under-5-years age group to include four new age groups, enhanced methods to account for stochastic variation of sparse data, and the inclusion of COVID-19 and other pandemic-related mortality-which includes excess mortality associated with the pandemic, excluding COVID-19, lower respiratory infections, measles, malaria, and pertussis. For this analysis, 199 new country-years of vital registration cause-of-death data, 5 country-years of surveillance data, 21 country-years of verbal autopsy data, and 94 country-years of other data types were added to those used in previous GBD rounds. FINDINGS The leading causes of age-standardised deaths globally were the same in 2019 as they were in 1990; in descending order, these were, ischaemic heart disease, stroke, chronic obstructive pulmonary disease, and lower respiratory infections. In 2021, however, COVID-19 replaced stroke as the second-leading age-standardised cause of death, with 94·0 deaths (95% UI 89·2-100·0) per 100 000 population. The COVID-19 pandemic shifted the rankings of the leading five causes, lowering stroke to the third-leading and chronic obstructive pulmonary disease to the fourth-leading position. In 2021, the highest age-standardised death rates from COVID-19 occurred in sub-Saharan Africa (271·0 deaths [250·1-290·7] per 100 000 population) and Latin America and the Caribbean (195·4 deaths [182·1-211·4] per 100 000 population). The lowest age-standardised death rates from COVID-19 were in the high-income super-region (48·1 deaths [47·4-48·8] per 100 000 population) and southeast Asia, east Asia, and Oceania (23·2 deaths [16·3-37·2] per 100 000 population). Globally, life expectancy steadily improved between 1990 and 2019 for 18 of the 22 investigated causes. Decomposition of global and regional life expectancy showed the positive effect that reductions in deaths from enteric infections, lower respiratory infections, stroke, and neonatal deaths, among others have contributed to improved survival over the study period. However, a net reduction of 1·6 years occurred in global life expectancy between 2019 and 2021, primarily due to increased death rates from COVID-19 and other pandemic-related mortality. Life expectancy was highly variable between super-regions over the study period, with southeast Asia, east Asia, and Oceania gaining 8·3 years (6·7-9·9) overall, while having the smallest reduction in life expectancy due to COVID-19 (0·4 years). The largest reduction in life expectancy due to COVID-19 occurred in Latin America and the Caribbean (3·6 years). Additionally, 53 of the 288 causes of death were highly concentrated in locations with less than 50% of the global population as of 2021, and these causes of death became progressively more concentrated since 1990, when only 44 causes showed this pattern. The concentration phenomenon is discussed heuristically with respect to enteric and lower respiratory infections, malaria, HIV/AIDS, neonatal disorders, tuberculosis, and measles. INTERPRETATION Long-standing gains in life expectancy and reductions in many of the leading causes of death have been disrupted by the COVID-19 pandemic, the adverse effects of which were spread unevenly among populations. Despite the pandemic, there has been continued progress in combatting several notable causes of death, leading to improved global life expectancy over the study period. Each of the seven GBD super-regions showed an overall improvement from 1990 and 2021, obscuring the negative effect in the years of the pandemic. Additionally, our findings regarding regional variation in causes of death driving increases in life expectancy hold clear policy utility. Analyses of shifting mortality trends reveal that several causes, once widespread globally, are now increasingly concentrated geographically. These changes in mortality concentration, alongside further investigation of changing risks, interventions, and relevant policy, present an important opportunity to deepen our understanding of mortality-reduction strategies. Examining patterns in mortality concentration might reveal areas where successful public health interventions have been implemented. Translating these successes to locations where certain causes of death remain entrenched can inform policies that work to improve life expectancy for people everywhere. FUNDING Bill & Melinda Gates Foundation